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ABSTRACT
A new efficient type of gadolinium-based theranostic agent (AGuIX®) has recently been developed for MRI-guided
radiotherapy (RT). These new particles consist of a polysiloxane network surrounded by a number of gadolinium chelates,
usually 10. Owing to their small size (,5nm), AGuIX typically exhibit biodistributions that are almost ideal for diagnostic
and therapeutic purposes. For example, although a significant proportion of these particles accumulate in tumours, the
remainder is rapidly eliminated by the renal route. In addition, in the absence of irradiation, the nanoparticles are well
tolerated even at very high dose (10 times more than the dose used for mouse treatment). AGuIX particles have been
proven to act as efficient radiosensitizers in a large variety of experimental in vitro scenarios, including different
radioresistant cell lines, irradiation energies and radiation sources (sensitizing enhancement ratio ranging from 1.1 to 2.5).
Pre-clinical studies have also demonstrated the impact of these particles on different heterotopic and orthotopic
tumours, with both intratumoural or intravenous injection routes. A significant therapeutical effect has been observed in
all contexts. Furthermore, MRI monitoring was proven to efficiently aid in determining a RT protocol and assessing
tumour evolution following treatment. The usual theoretical models, based on energy attenuation and macroscopic dose
enhancement, cannot account for all the results that have been obtained. Only theoretical models, which take into
account the Auger electron cascades that occur between the different atoms constituting the particle and the related
high radical concentrations in the vicinity of the particle, provide an explanation for the complex cell damage and death
observed.
Radiotherapy (RT) is the most commonly used non-
surgical cancer therapy, designed to apply ionizing
radiation at a sufﬁciently high cytotoxic dose to kill cells
within the tumour tissue.1 RT is primarily limited in its
ability to deliver therapeutic doses to the target tumour volume
whilst minimizing damage to the surrounding healthy tissue.2
Numerous solutions have been proposed to overcome this issue,
broadly falling into two main categories: (i) implementation of
advanced RT techniques enabling intensity-modulated radiation
ﬁelds [intensity-modulated radiation therapy (IMRT)] in order
to more precisely adapt the dose to the tumour target; (ii) de-
velopment of a new generation of therapeutic agents that sen-
sitize cells to ionizing radiation (radiosensitizers) by improving
dose efﬁcacy with their high density and high atomic number
(Z).3 High atomic number compounds may provide further
beneﬁt in the clinical setting by improving contrast properties
for radiological imaging. This would allow monitoring of the
radiosensitizing agent within the tumour. It would also facilitate
precise deﬁning of the tumour target to allow radiosensitization
without affecting healthy tissue. These types of agents are known
as “theranostic” agents.
Classical imaging contrast agents based on iodine for CT and
gadolinium complexes for MRI could all potentially prove ef-
fective theranostic agents. The use of inorganic nanoparticles for
radiosensitization was ﬁrst demonstrated by Hainfeld et al4 using
1.9-nm gold nanoparticles delivered systemically prior to irra-
diation in mice exhibiting EMT-6 mammary carcinomas. The
authors reported 1-year survival in 86% of animals treated under
these conditions compared with only 20% in those irradiated
without gold particle injection. The interest in researching in-
organic nanoparticles for the purposes of radiosensitization
stems from the unique properties of these particles. Firstly, their
innate high atomic number and density characteristics, lending
them higher mass energy absorption coefﬁcients than soft tis-
sues;5 secondly, their multimodality offering the potential for
theranostic applications, such as obtaining imaging functionality
in addition to radiosensitizing properties;6 thirdly, their partic-
ular morphology that enables tailored biodistribution, with the
potential for passive targeting due to the enhanced permeability
and retention (EPR) effect.7 In recent studies, nanoparticles have
been shown to induce a highly heterogeneous energy distribu-
tion at the subcellular scale, leading to complex cell damage near
the particles.8 This could be a key factor in determining overall
response.
Despite the efﬁcacy of gold particles as radiosensitizers, gold may
not be the only suitable high atomic number theranostic can-
didate, given the lack of sensitivity afforded by CT classically
using gold nanoparticles. The combination of MRI and RT
technologies for a single image-guided treatment holds clear
potential for improved clinical outcome, as emphasized by the
development of new fused instruments combining these two
modalities. In this context, gadolinium-based particles appear
particularly interesting, since their MRI contrast properties are
signiﬁcantly higher than those of molecular complexes in cur-
rent use, and they also present a strong and promising radio-
sensitizing effect.
MRI AND ITS RELEVANCE IN MODERN
RT METHODS
The optimization of radiological imaging is essential for im-
proving target delineation at the diagnosis and RT treatment
planning stages. The use of conformal RT with high-precision
volume targeting, particularly with the tightly conformal doses
produced by IMRTor stereotactic radiosurgery (SRS), makes the
accurate determination of targeted volume and critical organs
essential. CT imaging is commonly used in three-dimensional
RT treatment planning in order to outline tumour volume and
critical organs, ensuring the superior spatial accuracy and elec-
tron density information required for dose calculation algo-
rithms. Yet, the poor soft-tissue contrast obtained with this
method may complicate delineation. MRI offers improved soft-
tissue contrast and resolution, rendering it increasingly popular
for RT. Variations on imaging parameters, such as proton den-
sity and tissue relaxation times, can have a signiﬁcant impact on
the image contrast from soft-tissue structures. This ﬂexibility in
varying tissue contrast or signal intensities provides much better
characterization of soft tissues than can be achieved with radi-
ography. One disadvantage of MRI could involve its capacity for
spatial accuracy, although combining CT with MRI scans may
correct this inaccuracy and potentially beneﬁt treatment plan-
ning. By combining the two techniques, the complementary
information contained in both provides a more accurate deﬁ-
nition of both tumour and healthy tissues.
For a more reliable medical diagnosis, paramagnetic contrast
agents (T1 or positive contrast agents) are often administered to
patients, with the objective of enhancing the native contrast
between different tissues. Compared with CT, contrast-enhanced
MRI is even more successful at lesion detection, particularly for
small lesions, and boasts several advantages. These include im-
proved soft-tissue contrast, the absence of bone artefacts, fewer
partial volume effects and direct multiplanar imaging. Advanced
MRI techniques, including spectroscopy, diffusion and diffusion
tensor, along with perfusion and functional imaging, offer the
added beneﬁt of increased physiological data to supplement the
anatomic or structural information provided by conventional
MRI.9
Of all the imaging techniques available in routine practice, MRI
performed with a gadolinium-based contrast agent has been
recognized as the gold standard in numerous settings for iden-
tifying the number, size, characterization (heterogeneity and
necrotic area etc.) and location of metastatic lesions along with
the invasion of surrounding tissues and critical structures.
Taking the case of intracranial metastasis as an example, SRS is
the treatment of choice when metastases detected on imaging
are few in number (3–5, maximum) or small in size (,30mm).
This treatment also offers the advantage of being minimally
invasive and can be used to treat inaccessible lesions, in contrast
to surgical resection.10,11 With SRS, the capability of MRI to
precisely delineate lesion borders in three dimensions is in-
strumental in reducing recurrence rates and minimizing radiation
necrosis in the surrounding tissue. MRI is not only able to gen-
erate pathophysiological and functional data pertaining to the
central nervous system but also to the lung,12,13 breast,14,15
prostate,16 and head and neck17 regions, offering the added
possibility of identifying individuals at risk of developing
radiation-induced late effects, in addition to monitoring the ef-
ﬁcacy of interventions to prevent or improve them. It is therefore
of paramount importance that MRI protocols, including the
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selection of the appropriate gadolinium-based contrast agent, are
optimized in order to ensure accurate lesion imaging.9
GADOLINIUM, A KEY ELEMENT AT THE JUNCTURE
BETWEEN IMAGING AND THERAPY
Gadolinium is the most widely used paramagnetic element
for MRI-positive contrast agents, favoured for its seven unpaired
electrons and relatively long electronic relaxation times.
Gadolinium-based contrast agents impact on proton relaxation
times in the following manner: protons in the organism produce
energy when subjected to radiofrequency, which, when correctly
ampliﬁed, are transformed into the MR signal. Proton relaxation
times are typically characterized by two parameters: T1 (longi-
tudinal relaxation) and T2 (transverse relaxation). Gadolinium-
containing agents reduce T1 and T2 relaxation times, thus causing
a change in the signal of the injected structures, such as the
vessels, parenchyma or lesions.
In addition to the paramagnetic features of gadolinium ions,
which are extremely useful for enhancing MRI contrast, the
gadolinium element exhibits other properties that are advanta-
geous to radiosensitization, related to its relatively high atomic
number (Z5 57). During RT, these high atomic number species
undergo inner-shell ionization, where one of the deeply bound
electrons is removed with high efﬁciency, compared with results
with the low atomic number species predominantly found in
living systems. Several Auger emissions can be produced si-
multaneously from this single inner-shell ionization process,
known as an Auger cascade. As a result, these low-energy elec-
trons deposit their energy locally, and this effect can even be
ampliﬁed if the high atomic number elements are associated in
a small solid particle. This highly localized deposition of energy
provides the kind of efﬁcient performance usually associated
solely with heavy ion facilities, yet using conventional linear
particle accelerators (LINAC). Nevertheless, the physical basis of
radiosensitization and the resulting biological mechanisms have
recently been reviewed.8,18
In recent studies, different strategies have been explored per-
taining to the design of gadolinium-containing nano-objects.
These consisted of either synthesizing crystalline nanoparticles
containing gadolinium (gadolinium oxides,19 ﬂuoride,20
phosphate21,22 and vanadates23) or functionalizing different types
of nanoparticles using gadolinium chelates or ions, either within
the structure or on the surface (with liposomes,24 zeolites,25
mesoporous silica,26,27 quantum dots,28 lipid particles,29 gold
nanoparticles,30,31 carbon nanotubes32,33 and ultrasmall
polysiloxane34,35). Yet, out of all the gadolinium-based com-
pounds described so far, while most have been developed for MRI
application, very few have been described as radiosensitizers.
The most extensively reported and developed gadolinium-based
compound for radiosensitization is motexaﬁn gadolinium
(MGd), a porphyrin-like macrocycle that forms highly stable
complexes with large metal cations. MGd is a tumour-selective
radiation sensitizer detectable by MRI36 that is currently subject
to Phase III clinical development as an adjuvant to RT for brain
tumour management. Although this compound is rapidly
cleared from blood and healthy tissue, it remains in brain
tumours, resulting in a MGd concentration increase observable
in the tumour tissue.37 Although MGd does not cross the
blood–brain barrier (BBB) in healthy brains, MRI revealed its
uptake in the brain tumour tissue of glioblastoma multiform
(GBM) patients.38 The reported MGd mechanism of action is
thought to be less signiﬁcantly modulated by the high atomic
number of gadolinium in MGd, but rather more directly asso-
ciated with complex biochemical processes. This is accounted
for by its sensitization of cells through oxidative stress caused by
redox cycling, leading to an enhanced radiation response.39 The
positive effects of a molecule on radiosensitization and chemo-
sensitization are possibly unrelated to the actual presence of the
drug and perhaps linked rather to the result of a late MGd effect
on energy metabolism or other cell mechanisms involved in
enhancing radiosensitivity. MGd (i) initiates an imbalance in the
radical scavenging capability of the targeted cells, with an ele-
vated intracellular reactive oxygen species (ROS) production;
(ii) negatively regulates the ability of a cell to eliminate ROS; and
(iii) inhibits DNA synthesis and repair processes by suppressing
the activity of the enzyme ribonucleotide reductase.37
Radiosensitization has also been achieved using molecular
contrast agents such as Magnevist® (Bayer Pharma, Berlin,
Germany) in gadolinium neutron capture therapy (Gd-NCT),
an experimental cancer treatment based on the physical prin-
ciple that neutron capture with 155Gd and 157Gd ensures the
release of local high-dose radiation, such as g-rays and electrons.
While an alpha-enhancement factor of 2.3 was obtained with the
application of Magnevist on human SW-1573 cells, researchers
have observed that Magnevist could not radioenhance the cells
for g-ray irradiation. They thus concluded that Gd-NCT, when
using a non-toxic concentration of gadolinium, is effective in
inducing cell death and chromosome aberrations in in vitro cell
cultures following neutron radiation.40 Based on these ﬁndings,
we can therefore deduce that, in g-ray irradiation experiments,
the nanostructure of gadolinium, such as its unique molecular
or clustering of particles, may play a relevant role.
Chitosan nanoparticles containing gadolinium have also been
developed and synthetized for radiosensitization; they have
successfully been incorporated into cells in vitro,41 with higher
incorporation as than molecular contrast agents. Following
intratumoural (IT) injection in melanoma-bearing mice, ther-
mal neutron irradiation was applied to the tumour site, and the
14-day monitoring of tumour growth revealed tumour growth
delay.42 Designing radiosensitizing gadolinium nanoparticles in
order to monitor their distribution using MRI thus constitutes
a real asset. The high resolution available with MRI enables the
tumour to be accurately located and helps determine the most
suitable time for irradiation when a favourable distribution is ob-
served. Of the different nanomaterials containing gadolinium, ul-
trasmall gadolinium-polysiloxane particles appear a very attractive
option.
DESCRIPTION AND IMAGING PROPERTIES OF
AGuIX NANOPARTICLES
Nanoparticle synthesis
With the aim of developing nanoparticles for theranostic
approaches in cancer RT, our group synthesized ultrasmall
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gadolinium-based nanoparticles. These were comprised of
polysiloxane and surrounded by gadolinium chelates
[either diethylenetriaminepentaacetic acid (DTPA) or
1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic
acid (DOTAGA)] covalently grafted to the polysiloxane in-
organic matrix. These nanoparticles exhibited a sub-5-nm size
and diameter of approximately 3 nm, which is well suited for
renal elimination.43 To obtain such small sizes, our laboratory
established an original synthesis method.34,35 The ﬁrst generation
of AGuIX® nanoparticles was developed with DTPA, an acyclic
ligand, already used as a commercial contrast agent named
Magnevist.44 To further improve thermodynamic and kinetic
constants for gadolinium chelation, the same synthesis was per-
formed with DOTAGA, a cyclic ligand. For these nanoparticles,
a complexation constant (logb110) of 24.78 was calculated, almost
precisely the same as that of the commercial agent DOTAREM®
(Guerbt LLC, Aulnay-sous-Bois, France) (25.58), assessed in the
same conditions. There were approximately 10 chelates per
nanoparticle, with an approximate mass of 10 kDa (Figure 1).
Similar biodistributions and radiosensitizing effects were observed
for each of the DTPA or DOTAGA nanoparticles described in this
article.
Biodistribution in healthy animals
AGuIX nanoparticles have been proven as effective MRI-positive
contrast agents. The nuclear magnetic relaxation dispersion
proﬁle demonstrated that the AGuIX particles display a longi-
tudinal relaxivity (r1) two to three times higher than that of
DOTAREM, depending on the intensity of the magnetic ﬁeld
[e.g. 11.4mmol21 s21 and a ratio transverse relaxivity (r2)/r1 of
1.14 at 1.4 T for the AGuIX nanoparticles with DOTAGA]. The
nanoparticles were then injected intravenously into healthy mice
[80ml at 40mM in (Gd31)], with MRI then performed at 7 T.
A rapid signal was detected in the kidneys, then in the bladder
5min after injection, followed by a decrease of the signal due to
particle elimination (Figure 2). The residence time of the
nanoparticles was approximately double that of the DOTAREM,
13.2 and 6.8min in mice for AGuIX and DOTAREM,
respectively.
By labelling the nanoparticles using 111In, we were able to
conduct biodistribution studies with a precise quantiﬁcation of
their proportion in each organ following animal sacriﬁce.
Healthy animals were observed exhibiting an uptake in all
organs, with the exception of the kidneys and bladder, ,0.2% of
the injected dose 3 and 24 h following intravenous nanoparticle
injection. This conﬁrmed the nanoparticles’ renal elimination
(Figure 3).34
Another speciﬁc single photon emission computed tomography
study with 111In labelling has been performed on brain tumour-
bearing animals with longer times following intravenous in-
jection. This study demonstrated that .95% of the nano-
particles were eliminated from the body 18 days after injection.45
Figure 1. Representation of the AGuIX® nanoparticle. Gadoli-
nium atoms are chelated by 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid derivatives. The polysiloxane matrix is
composed mainly of silicon and oxygen. The nanoparticles
display a high gadolinium content (15 wt%), sub-5-nm size,
approximate mass of 10kDa, and the following chemical
formula Gd10Si40C200N50O150Hx.
Figure 2. T1 weighted image of a slice, including a kidney (K)
and bladder (B) of a mouse before (t50), 5min after and
60min after intravenous injection of AGuIX® nanoparticles.
Figure 3. 111In-labelled AGuIX® biodistribution at 3 and 24h
following intravenous injection in C57Bl6/J mice. G, gland;
L, left; ID, injected dose; p.i., post injection; sal, salivary.
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Brain angiographs were additionally performed in order to
compare the contrast obtained using AGuIX with that using
DOTAREM at 7 T for the same concentration of gadolinium. A
signiﬁcantly higher contrast was observed for the AGuIX
nanoparticles in comparison with DOTAREM, which can be
accounted for by the longer residence times observed in
the blood vessels for the particles, as well as by their higher
longitudinal relaxivity r1 (6mmol
21 s21 for the AGuIX and
3mmol21 s21 for the DOTAREM at 7 T).
Another route of administration was explored in healthy mice,
testing the possibility of lung pathology imaging techniques with
administration via the airways. A clear increase in contrast was
observed when conducting an ultrashort echo time (UTE) MRI
investigation, a few minutes after administering AGuIX nano-
particles. Different particle concentrations were investigated
(Figure 4), with improvements observed up to a maximum
concentration of 50mM in Gd31 (signal enhancement of 2666
14%). At higher concentrations, a decrease in signal was ob-
served, probably owing to the T2 effect. The temporal evolution
of signal enhancement recorded in the lungs was ﬁtted by means
of a monoexponential, and a lifetime of 1496 51min was de-
termined.46 Being small in size, the nanoparticles passed from
the lungs into the vascular system and were eliminated by the
kidneys and bladder, as expected. In line with previous ﬁnd-
ings,35 no signal was detected in the spleen or liver following
intravenous injection. For both differing administration routes,
a relatively rapid renal elimination was observed that provided
a better contrast in the diseased area and limited the potential
toxicity risks.
Toxicity
Throughout all the synthesis optimizations, formulations and
pre-clinical experiments, no real toxicity issues were reported.
The chemical composition was based on well-accepted com-
pounds, namely an association of polysiloxane (a silica de-
rivative) and biocompatible gadolinium chelates presenting high
stability. Regular animal experiments were performed without
any toxicity when using gadolinium concentrations comparable
to those in therapeutic use for gadolinium chelate contrast
agents (i.e. between 5 and 10mM of gadolinium injected per
mouse).
Speciﬁc preliminary studies evaluated the maximum tolerated
dose pertaining to the nanoparticles in rodents and monkeys.
For rats, no adverse effects were observed on repeated weekly
nanoparticle injections for 3 weeks, administering concen-
trations ranging from 250 to 750mg kg21. For monkeys, re-
peated injections of nanoparticles, namely 12 in 6 weeks, with
concentrations ranging from 100 to 500mg kg21 were carried
out, with no adverse effects observed. These experiments led to
an equivalent human dose in the range of 100mg kg21 being
calculated for clinical trial testing.
In addition, an acute toxicological study was conducted on the
lungs and kidneys following nanoparticle administration via the
airways (50ml of AGuIX at 50mM in Gd31).47 No signiﬁcant
increase in inﬂammatory cells was observed in the lungs, and
there was no pathological change in the alveolar–capillary bar-
rier. Moreover, there was no signiﬁcant difference in the creat-
inine levels between the AGuIX and control groups recorded,
whereas a signiﬁcantly elevated creatinine level was noted fol-
lowing treatment by lipopolysaccharide from Escherichia coli
serotype, as expected. This suggests the absence of any signiﬁ-
cant nephrotoxicity relating to AGuIX, even in cases of pro-
longed renal uptake.47
Biodistribution in tumour-bearing animals
Published almost 30 years ago, the studies performed by
Maeda48 demonstrated the ability of intravenously injected
macromolecules or nanoparticles to passively accumulate in
tumours. This EPR effect7 can at times prove controversial for
human application comprising drug delivery with large nano-
particles. In cases using ultrasmall solid particles, the EPR effect
may, however, offer advantages, particularly for AGuIX nano-
particles of sizes approaching 10 kDa that exhibit rapid renal
elimination.
We opted to use orthotopic rather than heterotopic brain tu-
mour models for our analysis of nanoparticle behaviour in
a biologically relevant context. In healthy mice, AGuIX nano-
particles do not leak through the BBB, which is often compro-
mised in a pathological brain, thereby allowing drugs to
accumulate in the tumour. By injecting AGuIX nanoparticles
intravenously into 9L glioma-bearing rats, we were able to in-
crease tumour contrast 1min following the injection (Figure 5).
In the healthy surrounding tissue, the signal was seen to increase
slightly a few minutes after the injection before rapidly de-
creasing. In contrast to this ﬁnding, we detected a signiﬁcant
MRI signal enhancement in the tumour, which then plateaued,
Figure 4. Axial slices of the mouse lungs (a) prior to contrast agent administration (t50), (b) following administration of 5mM and
(c) 50mM (of Gd31) of AGuIX® nanoparticles.
Review article: Theranostic gadolinium-based nanoprobes to improve radiotherapy BJR
5 of 15 birpublications.org/bjr Br J Radiol;87:20140134
remaining detectable for up to 24 h post injection. The rapid
signal decrease in the healthy zone, combined with the particle
retention in the tumour, ensures a large window for performing
RT. The best time to activate the nanoparticles with X-rays
corresponds to precisely when the concentration is at its highest
in the tumour and lowest in the healthy tissue, enabling a high
therapeutic effect combined with minimum secondary effects.
In order to provide an example of metastasis visualization,
nanoparticles were intravenously injected into rats with hepatic
colorectal cancer metastases and visualized by means of a 9.4-T
apparatus. This study sought to evidence the adequacy of AGuIX
in the most recently developed models of MRI devices, which are
designed to operate at greater ﬁelds, so as to improve imaging
contrast. As we expected, the AGuIX nanoparticles demon-
strated better signal-to-noise ratio (SNR), contrast-to-noise ratio
(CNR) and lesion enhancement in comparison with DOTAREM
when using the same quantities of injected gadolinium (Table 1).
[P Fries, 2014, personal communication]
AGuIX nanoparticles have also been used to detect orthotopic
tumours via different administration routes. The animals in this
experiment were female NMRI immunodeﬁcient mice that had
been orthotopically implanted with H358-Luc bioluminescent
lung carcinoma cells. Tumour growth was monitored by means
of both bioluminescence and CT.
In a recent Proceedings of the National Academy of Sciences
publication, intratracheal administration of nanoparticles was
compared with intravenous injection of particles at different
concentrations, as well as to intravenous injection of DOTAREM
(Table 2).49 Improved tumour contrast was observed with
AGuIX nanoparticles following administration via the airways in
comparison with intravenous injection (CNR of 15.86 1.3 and
4.86 1.8, respectively), despite the quantity of gadolinium
brought by the nanoparticles being four times lower. The
marked tumour contrast observed with intratracheal adminis-
tration cannot be accounted for solely by the EPR effect. One
possible explanation for particle accumulation within the tu-
mour is that once the particles reached the alveoli, they were
able to directly access the tumour owing to the lack of tissue
barrier. The reproducibility of the method was assessed by
leaving a 3-day gap between injecting and imaging (Days 35 and
38, respectively, following tumour implantation), which pro-
duced the same CNR and signal enhncement results (Figure 6).
In summary, MRI experiments have demonstrated that AGuIX
nanoparticles enhance contrast much more efﬁciently than
does DOTAREM owing to their higher r1 per gadolinium, higher
residence time in the body and speciﬁc accumulation in tumours,
primarily as a result of the EPR effect. MRI visualization of the
particles is the ﬁrst step for personalized medicine. Once their
presence has been detected and ideally their concentration quan-
tiﬁed using MRI, a radiotherapeutic protocol can be proposed
based on the particles’ biodistribution measured in the patient.
STATE-OF-THE-ART METHODS USING
NANOPARTICLES AS RADIOSENSITIZERS WITH
CONTRAST PROPERTIES
High atomic number gold (Z5 79) and gadolinium (Z5 64)
particles were used for theranostic applications pertaining to CT
Figure 5. T1 weighted images of the brain of a 9L gliosacrcoma-
bearing rat before and 1, 10 and 17min after AGuIX® injection.
Temporal evolution of the MRI signal in the tumour (diamonds)
and in an equivalent surface in tumour tissue in the left
hemisphere (squares). a.u., arbitrary unit.
Table 1. Evaluation of signal-to-noise ratio (SNR),
contrast-to-noise ratio (CNR), and lesion enhancement (LE)
in the tumour tissue of the liver in a rat model of hepatic
colorectal cancer metastasis following injection of
0.01mmol kg21 body weight of gadolinium contained in
AGuIX® or DOTAREM®
Contrast agent AGuIX DOTAREM
SNR 29.66 2.8 18.66 1.2
CNR 6.46 1.2 4.06 0.6
LE 14.96 2.8 3.86 2.7
Data show as mean 6 standard deviation.
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and radiosensitization owing to their strong X-ray absorption
coefﬁcients resulting in improved contrast over a wide energy
range compared with soft tissues (Figure 7).5,50
The landmark study by Hainfeld et al4 has been succeeded by
numerous experimental reports using particles with different
physicochemical properties and photon source energies.8,51 In
parallel, several theoretical models have been developed in the
attempt to predict overall sensitization levels based on the mass
energy absorption coefﬁcients of gold and soft tissue, gold
concentration and source energy. These have taken into account
the fact that two major processes govern the interaction between
matter and radiation for energies comprised between 1 and 0.9
million electron volts approximately: the Compton effect and
the photoelectric effect. At low energies, typically ,150 keV, the
photoelectric effect dominates. This consists of the absorption of
the photon by bound electrons, followed by the ejection of one
electron, with re-organization of the other electrons of the atom.
As displayed in Figure 7, at this energy range, the mass energy
absorption coefﬁcient is signiﬁcantly higher for gadolinium in
comparison with soft tissues and water. At higher energies,
particularly in the million electron volts range commonly used
for RT, Compton interaction is the effect that predominates.
This consists of the inelastic scattering of the incident photon by
a bound electron, resulting in its ejection and the re-
organization of the electrons of the atom. For this process,
there is almost no absorption difference between soft tissues and
gadolinium. In these cases, all models have failed to accurately
predict the experimental ﬁndings. In fact, the observed radio-
sensitization levels were greater than those predicted by the
theory.3 As a result, radiosensitization has been attributed to
several biological mechanisms, such as oxidative stress, cell cycle
and bioavailability.8 When using AGuIX gadolinium-based
nanoparticles, however, these processes are unlikely to occur.
Following these ﬁndings, it was later demonstrated that the role
of the high atomic number nanoparticles submitted to ionizing
radiations was not related to the enhancement of the total dose
deposition in the medium, but due rather to the induction of
nano-sized spots of intense ionization. This was experimentally
described at the molecular scale by Porcel et al,52 who demon-
strated that platinum nanoparticles induced nano-sized damage
as a result of the production of nanoscopic radical clusters in
close vicinity to the nanoparticles. Similarly, McMahon et al53
reported that ionizing events in gold nanoparticles led to energy
depositions equivalent to hundreds of gray units, or even more,
in regions within a few hundred nanometres of the nanoparticle.
The primary cause of these effects is known to be the Auger
cascades occurring in nanoparticles, where single ionizing
events led to the emission of multiple low-energy secondary
Figure 6. Ultrashort echo time MR images at (a) 35 days and
(b) 38 days following tumour implantation (pinpointed by the
arrows) and intratracheal administration of 50ml at 50mM of
AGuIX® nanoparticles. Tumour presence was confirmed by
bioluminescence imaging and histology. Adapted with permis-
sion from Bianchi et al.49
Figure 7. Comparison of photon mass energy absorption
coefficients for gadolinium and soft tissues. Adapted from
Hubbell and Seltzer.50
Table 2. Evaluation of signal enhancement (SE) and contrast-to-noise ratio (CNR) in lung tumours with AGuIX® and DOTAREM®
administrated intratracheally and intravenously at different concentrations
Contrast agent and
administration route
AGuIX via the
airwaysa
AGuIX via i.
v.b
AGuIX via i.
v.c
DOTAREM via i.
v.b
SE 120.96 30.2 73.96 4.5 31.36 7.8 23.56 5.6
CNR 15.86 1.3 8.36 1.3 4.86 1.8 2.96 2.0
i.v., intravenous injection.
a
50ml at 50.0mM.
b
200ml at 50.0mM.
c
200ml at 12.5mM.
Data shown as mean 6 standard deviation.
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electrons that deposit their energies in short ranges. Owing to
the proximity between high atomic number atoms, these cas-
cades are further ampliﬁed in nanoparticles, where electrons
emitted by one atom can excite neighbouring atoms in their
vicinity.
In the following sections of this article, we have reported experi-
mental data concerning the radiosensitizing effect of AGuIX par-
ticles, showing that, in addition to being recognized as a better
contrast agent than conventional molecular gadolinium complexes
for all magnetic ﬁelds, AGuIX could also prove effective as
a theranostic agent in clinical RT. We have particularly demon-
strated the AGuIX effect to be a function of (i) gadolinium con-
centration, as well as (ii) the nature and (iii) energy of the radiation
used in in vitro (the In vitro experiments: efﬁcacy at low and high
energies with small particle concentrations section) and in vivo (the
In vivo experiments section) conditions.
IN VITRO EXPERIMENTS: EFFICACY AT LOW AND
HIGH ENERGIES WITH SMALL
PARTICLE CONCENTRATIONS
In order to emphasize how signiﬁcant the radiosensitization
process is, we irradiated different tumour cells in the presence of
AGuIX nanoparticles. We then analysed the sensitizing en-
hancement ratios (SER), deﬁned as the survival fraction (SF)
ratios for the control cells (irradiation alone) to those of the
treated cells (irradiation combined with nanoparticles). Signiﬁ-
cant SER (ranging from 1.1 to 2.5) were observed, conﬁrming
that the particles induce a signiﬁcant radiosensitizing effect.
Several experiments have been performed testing a large range of
conditions, particularly using low gadolinium concentrations (from
0.1 to 1mM) and kiloelectron volt levels to higher voltages of
energy, such as the few million electron volts of energy used in
clinical conditions (Table 3). As expected, the nanoparticles
exhibited a radiosensitizing effect when subjected to irradiation
doses approaching the K-edge of the gadolinium, namely in the
kiloelectron volt range where the photoelectric effect predominates.
More surprisingly, a similar effect was also observed at higher en-
ergies, where the interactions are governed by the Compton dif-
fusion. Our own work was particularly focused on assessing the
energy range used for RT in clinical practice. For example, Barberi-
Heyob et al demonstrated that AGuIX nanoparticles induced a high
radiosensitizing effect on a human glioma cell line labelled U87-
MG. The authors found that 6MV (from 1 to 8Gy) irradiation of
cells incubated with nanoparticles at gadolinium concentrations
varying from 0.01 to 0.5mM led to SER ranging from 1.1 to 1.5 [C
Truillet, 2014, personal communication]. The study was completed
by Dutreix et al,56 concluding that AGuIX nanoparticles primarily
induce complex damage. This last experiment evaluated the
number of phosphorylated g-H2AX histones related to nucleic
double-strand DNA breaks. An 84% increase in the number of
double-strand breaks was observed following irradiation in the
presence of nanoparticles compared with that observed with irra-
diation alone.
Another study, performed by Rodriguez et al,57 was focused on
analysing SQ20B (head and neck squamous cell carcinoma) tu-
mour cells and their cancer stem cell subpopulation, applying
250-kV irradiation following particle incubation at 0.4 and 0.6mM
gadolinium concentration. As with the other cases, the presence of
particles during irradiation here caused an SF decrease, combined
with a signiﬁcant increase in the number of double-strand DNA
breaks (41% and 53% after exposure at 2 Gy for incubations
at 0.4- and 0.6-mM concentration, respectively). Further evi-
dence of the complex damage was provided by the shape of the
SF as a function of the deposited dose. Curve ﬁtting was con-
ducted by applying the following linear quadratic equation:
SF5 exp2[a3D1b3D3D], where a and b represent the initial
slope (probability of lethal event) and terminal slope (sublethal
events) constants, respectively, and D the irradiation dose. For
irradiation alone, the ﬁtting curve was characterized by very
similar values for a and b (0.04 and 0.05, respectively). Where
AGuIX (0.6mM in Gd31) was present, the b-value was almost
unchanged (0.03), whereas a was signiﬁcantly increased up to
0.5. This indicates a high level of direct lethal damage to cells. It
is interesting to note that the SF curves with the presence of
particles closely resembled those obtained with carbon ion ir-
radiation [SF5 exp2(a3D)], which is also known to induce
complex and irreversible DNA lesions. Lastly, irradiation with
ions was conducted, in the presence of nanoparticles, in order to
detect synergetic effects. Irradiation by means of He21 or C61
ions in the presence of particles led to SER with the same order
of magnitude (Table 3) as that obtained with photon irradiation.
This demonstrates that nanoparticle sensitization is universally
independent of the radiation type used. 45,54,55
In summary, a large variety of in vitro experiments have been
performed seeking to assess the potential usefulness of
gadolinium-based nanoparticles for radiosensitization under
different conditions. AGuIX has been proven capable of serving
as an efﬁcient radiosensitizer under the following conditions:
(i) with different radioresistant cell lines; (ii) at different photon
radiation energies ranging from kiloelectron volts to million
electron volts; (iii) at very small concentrations in gadolinium
(i.e. two orders of magnitude smaller than those required by
well-established macroscopic dose enhancement models); and
(iv) with different types of radiation: photons and fast ions. This
increased efﬁcacy is related to the formation of complex and
irreversible DNA damage, generated in the vicinity of the par-
ticles. Lastly, AGuIX injection can be easily included in tradi-
tional RT protocols, as an injection step is often part of
examinations using MRI or radiographic CT devices.
IN VIVO EXPERIMENTS
During in vivo experiments, different procedures can be applied
for particle administration. In order to obtain sufﬁcient radio-
sensitizing efﬁcacy, the quantity of gadolinium needed in the
tumour under irradiation has been estimated at between 1 and
10mg of gadolinium concentration per gram of living animal.
These concentrations have been estimated based on in vivo
results, and IT administration initially appears more adapted to
obtain them, especially for accessible tumours, such as hetero-
topic or surface tumours.
Intratumoural administration
IT administration has been evaluated for different types of
heterotopic human tumour models,57 including radiosensitive
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melanoma A375. This model was subcutaneously implanted
(Figure 8) into the ﬂank of mice, with an injected dose of ap-
proximately 4mmol (0.6mg). We allowed no delay between
injection and irradiation in order to minimize the particle escape
that occurs during the treatment.
The treatment was proven to have a positive effect upon tumour
development. Tumour size did, in fact, diminish signiﬁcantly
after only two irradiations. Yet after a time, during which the
tumour size decreased, some tumour regrowth was observed.
The particles’ usefulness in this context is particularly supported
by the advantage of AGuIX in enabling greater reduction and
even near-total suppression of tumour growth. To give a con-
crete view of the improvement enacted by the presence of par-
ticles during irradiation, the tumour volume growth was
quantiﬁed 25 days following treatment. In this experiment, tu-
mour volume had only increased by 3% under irradiation in the
presence of particles, compared with 82% in their absence.
Intravenous administration
While IT injection may initially appear to be an interesting
approach, its clinical application is unfortunately limited to
conditions where the tumours lie in the vicinity of the surface of
the body. This is particularly the case in head and neck can-
cers,57 which were previously chosen as a relevant example for
application. In order to treat deep cancers, as well as the me-
tastases formed over the different disease stages, systemic AGuIX
particle administration required investigation, which we con-
ducted via intravenous injection. This type of injection requires
additional information, in particular a detailed biodistribution
Table 3. Radiosensitizing effect of AGuIX® measured on various cell lines
Investigator
(team, town)
Radiation/energy Cell line
NP/incubation
time
Biological effect
K. Butterworth (personal
communication) (Queen’s
University, Belfast, UK)
225 keV
Prostate—DU145
From 0.1 to
5.0mMa/1 h
1.17, SF, 2.50
Glioblastoma—T98G SF5 1.25
Prostate—PC3 1.25, SF, 1.33
R. Berbeco58 (Harvard,
Boston, MA)
220 kVp X-ray Cervical carcinoma—HeLa 0.5mMb/1 h
SER4Gy5 1.50
DEF5 1.5
C. Rodriguez-Lafrasse57
(University Lyon, Lyon,
France)
250 kV
Head and neck squamous cell
carcinoma—SQ20B
0.4mMa/1 h
SF25 0.60 vs 0.72
(SER5 1.20)
0.6mMa/1 h
SF25 0.35 vs 0.72
(SER5 2.00)
SQ20B cancer stem cells 0.6mMa/1 h
SF25 0.6 vs 0.82
(SER5 1.40)
C. Rodriguez-Lafrasse
(University Lyon, Lyon,
France)54
250 kV
Head and neck carcinoma—
SQ20B
0.4mMa/1 h
SF25 0.61 vs 0.75
(SER5 1.22)
0.6mMa/1 h
SF25 0.37 vs 0.75
(SER5 2.14)
M. Dutreix (Institute Curie,
Paris, France)56
660 keV Glioblastoma—U-87MG
0.1mM/1h g-H2AX1 80% vs
irradiation only0.5mM/1h
R. Berbeco56 (Harvard,
Boston, MA)
6MV Cervical carcinoma—HeLa 0.5mMb/1 h
SER4Gy5 1.30
DEF5 1.2
M. Barberi-Heyob56 (CRAN,
Nancy, France)
6MV Glioblastoma—U-87MG
From 0.01 to
0.50mMb/24 h
SER from 1.10 to 1.50
G. Blondiaux (CERI, Orle´ans,
France)
Neutron cyclotron (Orle´ans,
France)
Mouse lymphoma—EL4
From 0.05 to
0.30mM
Estimated
SER3Gy. 2.00
S. Lacombe59 (University of
Paris-Sud, Orsay, France)
Ions He21 beam (Chiba,
Japan)
Chinese hamster ovary
carcinoma—CHO
1.0mM/6h SER5 1.14
S. Lacombe59 (University of
Paris-Sud, Orsay, France)
C61 beam (200MeV/uma)
(Chiba, Japan)
Chinese hamster ovary
carcinoma—CHO
1.0mM/6h SER4Gy5 1.50
C. Rodriguez-Lafrasse57
(University Lyon, Lyon,
France)
C61 (33.6 keVmm21) (Caen,
France)
Head and neck carcinoma—
SQ20B
0.3mMb/1 h SER5 1.33
0.6mMa/1 h SER5 1.59
DEF, dose enhancement fraction; NP, nanoparticle; SER, sensitizing enhancement ratio; SF, survival fraction.
Non-human cell lines are indicated.
a
AGuIX-diethylenetriaminepentaacetic acid.
b
AGuIX-DOTA.
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analysis, in order to ﬁrstly identify the mechanisms of particle
elimination and secondly to discriminate between the particle
concentration reached in the tumour and that in its healthy sur-
roundings. A strong concentration difference between the two
zones was expected owing to the previously described EPR effect.
To evaluate the efﬁcacy of intravenous injections, an orthotopic
implantation of 9L gliosarcoma tumour cells into rat brains was
performed in order to achieve appropriate tumour size 10 days
after implantation. Prior to irradiation, the animals were treated
using an intravenous injection of 1.4ml of AGuIX at 40mM
gadolinium, corresponding to 56mmol or approximately 10mg
of gadolinium. For an average rat weight of 250 g, this corre-
sponds to an injected dose of 40mg per gram of rat.
RT was performed after a delay of at least 15min following
AGuIX injection, allowing for particle elimination from the sur-
rounding healthy zones by renal clearance and also preventing any
potential undesired side effects. With the aid of the EPR effect,
this delay does not signiﬁcantly affect the particle concentration
within the tumour, at least for the ﬁrst few hours following ad-
ministration. It is this phenomenon, which was closely monitored
by MRI, that emphasizes the interest of using theranostic par-
ticles for image-guided therapy, particularly considering that
irradiation was performed 20min, 44min and 24 h post in-
jection (Figure 9—unpublished results).
As shown in Table 4, a signiﬁcant increase in median survival
time (MeST) was observed in both cases following irradiation,
compared with untreated animals or those treated only with
MRT. The presence of AGuIX during irradiation enabled an
increase in survival of the animals by a factor of 4.5 compared
with untreated animals and by a factor of 2 compared with
irradiated animals. More speciﬁcally, MeST was 90.0 and 95.5
days, when combining the intravenous injection of AGuIX and
irradiation after a delay of 20min or 24 h after injection, re-
spectively. These results are clearly accounted for by nanoparticle
biodistribution, which was studied in great detail previously.35
As a result of the EPR effect, and more particularly the retention
effect, the gadolinium concentration within the tumour (right
brain) was measured at 6 and 4mg per gram of brain for 20-min
and 24-h delays, respectively. In the healthy zone (left brain), it
was 5 and 0.5mg per gram for the two delays, respectively. The
extremely small reduction in gadolinium concentration ob-
served in the tumour region emphasizes the efﬁcacy of the EPR
effect in its ability to retain the nanoparticles inside the tumour,
especially when compared with healthy regions. This could ac-
count for the similar efﬁcacy that has been found for irradiations
performed both 20min and 24 h following nanoparticle
administration.
In addition, a comparison was made between the efﬁciency of
using particles (AGuIX) and molecular complexes such as
gadolinium chelates (DOTAREM) (Figure 10) under the same
experimental conditions of gadolinium concentration, irradia-
tion, and delay (20min) between injection and irradiation. The
shorter delay of 20min was chosen in order to maintain a high
gadolinium concentration in the tumour during irradiation,
especially for the gadolinium molecular contrast agent that is
almost entirely cleared from the tumour 24 h after
Figure 8. Relative tumour evolution after intratumoral (IT) AGuIX® injection. Tumour evolution without irradiation with only injection
of solution without particles (vehicle), 23 10 Gy irradiation alone with a delay of 24h (irradiation) or AGuIX injection (IT 4mmol, 23
4 mmol) followed by 23 10 Gy irradiation. Each value represents the mean6 standard error of the mean of tumour volume in mm3
(n = 8 per group).
Figure 9. Survival of 9L tumour-bearing rats following tumour
cell implantation after no treatment (five individual rats), only
irradiated by microbeam radiation therapy (MRT) and irradi-
ated by MRT 24h after the intravenous nanoparticle injection.
p.i., post injection.
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administration. Under these conditions, the survival curve
obtained with gadolinium chelates almost exactly correlated
with that obtained for irradiation alone: MeST obtained with
gadolinium chelates was 38 days, while that for irradiation alone
was 44 days. By contrast, the use of nanoparticles produced
a MeSTof 102.5 days. This survival difference observed between
particles and molecular chelates conﬁrms the particle usefulness
for radiosensitization. Firstly, this is supported by the better
retention observed of particles in the tumour. The second and
most signiﬁcant advantage of using particles is discussed in the
Nanoscale dose distribution and radiosensitization section.
Administration via the airways
The nanoparticle accumulation observed in lung tumours fol-
lowing nebulization presents an interesting opportunity for RT,
particularly considering that there is no accumulation in the
healthy zone. In this context, using an orthotopic H358 model
of human non-small-cell lung carcinoma grafted by means of
intratracheal administration of the cells, we determined that
radiosensitization activity was achievable when AGuIX particles
(50ml of approximately 20mM Gd31) were administered via the
airways. 1 month after tumour cell implantation, the mice were
divided into three groups: control (n5 6), irradiation (n5 11)
and AGuIX administration with irradiation (n5 11). Irradiation
was performed 24 h after AGuIX administration, consisting of
a single 10-Gy dose delivered with a radiation source emitting
200 keV (Figure 11).
Based on survival rates, no statistically signiﬁcant difference was
found between the control and irradiation-only groups (MeSTs
of 83 and 77 days, respectively; p5 0.926). However, the mice
survived much longer when they had received AGuIX particles
nebulized 1 day prior to RT. Their MeST was thus extended to
112 days (p5 0.028).
In order to optimize RT conditions when using radiosensitizing
agents, a large number of parameters must be optimized simulta-
neously. AGuIX administration is supported by an increasing
amount of pre-clinical evidence, yet further optimization of the
parameters, including the volume and concentration of gadolinium
in the injected solution, the source energy and fractionation
schedule, could further increase efﬁcacy. From both a medical and
economic viewpoint, a reduced dose requirement for producing the
same or an improved biological effect would reduce healthy tissue
complications and eventually even treatment costs. High radio-
sensitization effects have been demonstrated even with gadolinium
concentration ,1mg.g21 within the tumour. This is a signiﬁcant
ﬁnding, as it proves that even very small gadolinium concentrations
are sufﬁcient to induce a major effect on RTefﬁcacy. In particular, it
indicates that translation of this method towards early-phase clin-
ical use is a realistic possibility with low quantities of nanoparticles
(fewer grams per RT). The gadolinium quantity administered for
therapy with AGuIX nanoparticles was, in fact, very similar to that
currently injected for MRI, where gadolinium is used in its
Table 4. Survival results obtained after a microbeam radiation therapy (MRT) experiment
Series Median survival time (days) Animals (n) ILS%
Non-irradiated 1 19.0 4 n/a
Irradiated 1 47.0 7 147.0
Irradiated 20min after injection 90.0 8 373.0
Non-irradiated 2 20.0 5 n/a
Irradiated 2 46.0 7 130.0
Irradiated 24 h after injection 95.5 6 377.5
ILS, increase in life span; MeST, median survival time; n/a, not applicable.
MRT irradiation was performed in cross-firing mode, applying 50-mm-wide microbeams with 200-mm spacing and a 10310-mm irradiation field
centred on the tumour.
The skin entrance dose was set at 400Gy for the peak and 20Gy for the valley [ILS5 (MeST irradiated2MeST non-irradiated)/MeST irradiated3 100].
Experiments were repeated for the “non-irradiated” and “irradiated” series.
Figure 10. Survival curves of 9L tumour-bearing rats treated
only by microbeam radiation therapy (MRT) (MRT, n= 15 rats);
by MRT 20min after injection of DOTAREM® (Guerbet, Aulnay-
sous-Bois, France) (DOTAREM, n= 16 rats; p=0.42 vs MRT);
and by MRT 20min after intravenous injection of AGuIX®
nanoparticles (AGuIX, n=8 rats; p=0.013 vs MRT 1 DOTAREM
and p=0.062 vs MRT). Irradiation was performed 10 days after
tumour implantation. MRT irradiation was conducted in cross-
firing mode, applying 50-mm-wide microbeams with 200-mm
spacing. The skin entrance dose was set at 400Gy for the peak
and 20Gy for the valley. Statistical analysis was performed
using log-rank test.
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molecular form as a contrast agent (0.1mmol kg21). Finally, con-
centration levels of gadolinium shown to be efﬁcient in RT appli-
cations can be compared with those of gold, where gold is used in
its particle form for the purpose of sensitizing.4,54,55 The gold
concentration of the injected particles was 1.9 g kg21 and that in the
tumour during irradiation was 7mgAug21. These values are over
two orders of magnitude greater than the concentration in gado-
linium that, in all in vivo studies using AGuIX, ranged between 1
and 5mgGdg21. RT performed in combination with radio-
sensitizing particles requires either around 150 g of gold or only
a few grams of gadolinium. This demonstrates that gadolinium
currently appears to represent a more realistic sensitizer than gold,
with the caveats of cell type and radiation source.
NANOSCALE DOSE DISTRIBUTION
AND RADIOSENSITIZATION
As described above, macroscopic dose enhancement predictions
based on energy attenuation and gadolinium concentration
suggest that no signiﬁcant enhancement would be seen with the
low concentrations used experimentally. Nevertheless, given the
relatively high atomic number and multiple electronic shells
exhibited by gadolinium, similar Auger cascades to those ob-
served with gold can be seen with this particle, leading to
comparable highly localized dose deposits in the vicinity of the
nanoparticle.
As illustrated, Figure 12 presents a model of the average radial
energy deposit in the vicinity of a gadolinium nanoparticle fol-
lowing a single ionizing event by a 80-keV X-ray. Owing to the
presence of multiple gadolinium atoms in close proximity, these
events display a high probability of triggering an Auger cascade,
leading to the production of multiple low-energy electrons de-
positing large amounts of energy in a short range near the nano-
particle. These particles represent the primary source of energy
deposition within a range of ,1mm from the particle (Figure 13).
Owing to the short range of these secondary electrons, these energy
depositions correspond to very high doses, namely 2Gy at 200nm
Figure 11. Radiotherapy protocol for orthotopic lung tumour-bearing mice. D, day.
Figure 12. Illustration of nanoscale effects around irradiated AGuIX® gadolinium nanoparticles. The average energy deposited
around an AGuIX nanoparticle following an ionizing event by an 80-keV X-ray was calculated using Geant4 (CERN, Meyrin,
Switzerland) as a function of distance from the nanoparticle. The primary sources of this energy deposition were Auger electrons
(dashed line) and photoelectrons (dotted line), with only a small contribution from other processes (dot-dash line). Owing to the
low energy of Auger electrons, they deposit their energy in a highly localized region around the nanoparticle, leading to highly
localized doses.
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and almost 10Gy at 100nm, along with hundreds to thousands of
gray units in the immediate proximity of the particle. These dra-
matic dose heterogeneities are associated with a range of biological
effects, including high production of damaging hydroxyl radicals
and other downstream processes. An additional signiﬁcant factor is
that, in the case of ion irradiation, highly localized doses of this
form are associated with an increased probability of inducing sig-
niﬁcant DNA damage and cell death levels.
Based on this observation, an analysis of the impact of using
gold nanoparticles in the local effect model suggested that these
heterogeneities play a signiﬁcant role in the greater-than-
expected sensitizing effects of gold nanoparticles.53 The fact
that similar highly localized dose depositions occurred in the
presence of gadolinium could, to some extent, explain the dis-
crepancy between simple macroscopic dose predictions and the
sensitizing effects we observed.
CONCLUSION
This review has demonstrated that gadolinium-based nano-
particles hold signiﬁcant potential as theranostic agents. AGuIX
particles, in particular, exhibit unique properties of interest for
use not only as an MRI agent for tumour detection but also
a radiosensitizer for different radiation types, including photons
and fast ions, at different energies, and even at low nanoparticle
concentrations. AGuIX particles consist of a polysiloxane net-
work surrounded by gadolinium chelates (generally DTPA or
DOTAGA). Owing to their small size (,5 nm) and low mass
(approximately 10 kDa), these particles are characterized by
biodistributions that are ideal for diagnostic and therapeutic
purposes. Following intravenous injection, the particles are
rapidly eliminated from the body via the renal route and ac-
cumulate in tumours up to concentrations reaching 1% of
injected dose per gram. This passive accumulation that occurs as
a result of the EPR mechanism can be further enhanced by active
targeting through peptide functionalization on the surface of the
particle.49 These particles are always non-toxic, regardless of the
administration route chosen (intravenous injection and nebuli-
zation). They have also been demonstrated in vitro to be efﬁcient
radiosensitizers in a large variety of situations, including dif-
ferent radioresistant cell lines and photon radiation energies
ranging between kiloelectron volt and million electron volts. This
efﬁciency is related to the formation of a high level of complex
and irreversible DNA or cell membrane damage generated in the
vicinity of the particles. Finally, the in vivo efﬁcacy of AGuIX
particles has also been proven in different heterotopic and
orthotopic tumours. In the case of 9L gliosarcoma implanted into
rats, the therapeutic strategy exploited the theranostic character-
istics of AGuIX. Following intravenous injection, the gadolinium
concentrations of both the tumour and surrounding healthy tis-
sue were monitored by MRI, enabling RT to be commenced once
the concentration in the tumour was sufﬁciently high, and that in
the healthy tissue sufﬁciently low to avoid adverse effects. A sig-
niﬁcant increase in lifespan was then obtained for concentrations
in the tumour as low as a few micrograms per gram.
The radiosensitizing properties of this compound cannot be
described using the concept of macroscopic dose enhancement
based on the energy attenuation of the high atomic number
metal cations. The effect of gadolinium-based nanoparticles can
be attributed to the heterogeneity of dose deposition induced in
the medium. Brieﬂy, this phenomenon consists of gadolinium
undergoing electronic activation and Auger cascades in a similar
way to other high atomic number nanoparticles (gold and
platinum), leading to nanoscale dose deposits in the vicinity of
the nanoparticle.
This interpretation was supported by our calculation of the average
radial energy deposition in the vicinity of gadolinium particles after
a single ionizing event. This calculation demonstrated that the low-
energy electrons emitted by the nanoparticle deposit their energy in
its close vicinity. We found that the presence of several gadolinium
ions in the same nanoparticle could even lead to further ampliﬁ-
cation of the Auger cascade. As a result, the total energy deposition
corresponded to extremely high doses being applied close to the
particles. This dramatic heterogeneity in dose deposition appears
to cause the production of hydroxyl radical clusters and other
downstream processes, such as complex biological damage.
The preliminary data collected concerning the toxicity and po-
tential beneﬁts of AGuIX particle use in radiosensitizing appli-
cations has indicated that now is an opportune time to
commence systematic biological studies, with the objective of
initiating early phases ﬁrst of all in human trials.
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